购物车
- 全部删除
- 您的购物车当前为空
Irpagratinib (ABSK011)是一种靶向FGFR4(IC50<10 nM)的口服活性酪氨酸激酶抑制剂,可抑制FGFR4自磷酸化并阻断其信号转导至下游途径。在小鼠、大鼠和狗的PK研究中,Irpagratinib表现出高暴露量,并在皮下异种移植肿瘤模型中展示抗肿瘤活性。
Irpagratinib (ABSK011)是一种靶向FGFR4(IC50<10 nM)的口服活性酪氨酸激酶抑制剂,可抑制FGFR4自磷酸化并阻断其信号转导至下游途径。在小鼠、大鼠和狗的PK研究中,Irpagratinib表现出高暴露量,并在皮下异种移植肿瘤模型中展示抗肿瘤活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 现货 | |
50 mg | 询价 | 现货 |
产品描述 | Irpagratinib (ABSK011) is an orally active fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with specificity for FGFR4, exhibiting an IC50 of less than 10 nM. It effectively inhibits FGFR4 auto-phosphorylation and disrupts subsequent signal transduction to downstream pathways. Demonstrating high exposure in pharmacokinetic studies in mice, rats, and dogs, Irpagratinib also displays antineoplastic activity in subcutaneous xenograft tumor models [1]. |
别名 | ABSK011 |
分子量 | 570.59 |
分子式 | C28H32F2N6O5 |
CAS No. | 2230974-62-4 |
存储 | store at low temperature,keep away from moisture | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容